AstraZeneca Retained Earnings (Accumulated Deficit) 2010-2024 | AZN

AstraZeneca retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  • AstraZeneca retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $3.138B, a 823.04% decline year-over-year.
  • AstraZeneca retained earnings (accumulated deficit) for 2023 were $1.502B, a 361.67% decline from 2022.
  • AstraZeneca retained earnings (accumulated deficit) for 2022 were $-0.574B, a 133.57% decline from 2021.
  • AstraZeneca retained earnings (accumulated deficit) for 2021 were $1.71B, a 67.73% decline from 2020.
AstraZeneca Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $1,502
2022 $-574
2021 $1,710
2020 $5,299
2019 $2,812
2018 $5,683
2017 $8,221
2016 $8,140
2015 $11,834
2014 $13,029
2013 $16,960
2012 $17,955
2011 $17,888
2010 $18,272
2009 $16,198
AstraZeneca Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $3,138
2024-06-30 $1,847
2024-03-31 $-212
2023-12-31 $1,502
2023-09-30 $-434
2023-06-30 $-234
2023-03-31 $-1,825
2022-12-31 $-574
2022-09-30 $-2,471
2022-06-30 $-1,657
2022-03-31 $-1,228
2021-12-31 $1,710
2021-09-30 $2,200
2021-06-30 $5,335
2021-03-31 $4,089
2020-12-31 $5,299
2020-09-30 $1,876
2020-06-30 $1,913
2020-03-31 $448
2019-12-31 $2,812
2019-09-30 $1,865
2019-06-30 $3,265
2019-03-31 $3,682
2018-12-31 $5,683
2018-09-30 $5,162
2018-06-30 $5,879
2018-03-31 $6,164
2017-12-31 $8,221
2017-09-30 $7,001
2017-06-30 $6,930
2017-03-31 $6,263
2016-12-31 $8,140
2016-09-30 $6,381
2016-06-30 $6,858
2016-03-31 $8,075
2015-12-31 $11,834
2015-09-30 $10,707
2015-06-30 $11,649
2015-03-31 $10,305
2014-12-31 $13,029
2014-09-30 $13,893
2014-06-30 $15,504
2014-03-31 $14,992
2013-12-31 $16,960
2013-09-30 $17,200
2013-06-30 $17,184
2013-03-31 $16,368
2012-12-31 $17,955
2012-09-30 $16,328
2012-06-30 $16,406
2012-03-31 $16,020
2011-12-31 $17,888
2011-09-30 $18,614
2011-06-30 $18,340
2011-03-31 $17,332
2010-12-31 $18,272
2010-09-30 $17,233
2010-06-30 $19,359
2010-03-31 $18,061
2009-12-31 $16,198
2009-09-30 $16,901
2009-06-30 $15,369
2009-03-31 $12,969
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $197.819B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94